Targeting fasting and post-prandial triglycerides
Dr. Joanne Donovan, describes a potential novel approach to target fasting and post-prandial triglycerides with an oral agent that targets intestinal and liver PCSK9
Disclosure
Joanne M. Donovan MD PhD is Chief Medical Officer at Catabasis Pharmaceuticals, Inc
Share this page with your colleagues and friends: